Quel traitement de première ligne en cas de mutation activatrice de l'EGFR dans les cancers bronchiques non à petites cellules (CBNPC) disséminés ?

The presence of an activating mutation of the EGF-R in tumour cells encourages oncogenic addiction, which makes these tumors sensitive to EGF-R tyrosine kinase inhibitors, at least at one point. The management of patients who may present with these mutations should therefore be oriented towards the option of proposing a targeted therapy. We will examine how to manage patients with non-squamous cell NSCLC from diagnosis. We will also examine which treatments should be offered as first-line treatments.